<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552461</url>
  </required_header>
  <id_info>
    <org_study_id>U2990s</org_study_id>
    <nct_id>NCT00552461</nct_id>
  </id_info>
  <brief_title>Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis</brief_title>
  <acronym>PAP</acronym>
  <official_title>Prospective Open-Label Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Carolina University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>East Carolina University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the use of rituximab is effective in
      treating pulmonary alveolar proteinosis by leading to an improvement in lung function and
      disease status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to conduct a prospective, open-label 6-month trial of rituximab in
      patients who present with symptomatic primary or idiopathic PAP. A total of 10 subjects with
      primary PAP will be enrolled over 12 months at East Carolina University. Patients over age 18
      with a clinical diagnosis of moderate symptomatic idiopathic PAP, established by appropriate
      clinical history, radiographic and physiologic findings, presence of circulating anti-GM-CSF
      antibody, and confirmatory findings on bronchoscopy with bronchoalveolar lavage and/or
      open-lung biopsy will be recruited. Patients with newly diagnosed PAP or established disease
      may be considered for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate symptomatic, physiologic and radiographic effects of therapy</measure>
    <time_frame>6-months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the overall tolerability of therapy and the requirement for therapeutic whole-lung lavage</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pulmonary Alveolar Proteinosis</condition>
  <condition>Primary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>IV, 1000 mg, two weeks, 2 times</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rituxan</other_name>
    <other_name>MabThera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary PAP (new or chronic) with presence of anti-GM-CSF antibody

          -  Moderately symptomatic disease with PaO2 &lt;70 on room air and on less than 6 L/min
             oxygen

          -  Able to give written informed consent and comply with the requirements of the study

          -  Adequate renal and liver function

          -  Negative serum pregnancy test (for women of child bearing age) and on acceptable birth
             control during and after study completion

        Exclusion Criteria:

          -  Severe PAP and requires in-patient care and more urgent therapy with bilateral whole
             lung lavage

          -  Treatment with any investigational agent within 4 weeks of screening

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies

          -  History of HIV, recurrent significant infection or recurrent bacterial infections

          -  Known active bacterial, viral, fungal, mycobacterial, or other infection

          -  Ongoing use of high dose steroids (&gt;10mg/day) or unstable steroid dose

          -  Significant cardiac or pulmonary disease or blood disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mani S Kavuru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Carolina University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irene Marshall, PA-C</last_name>
    <phone>252-744-5888</phone>
    <email>marshalli@ecu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mani S Kavuru, MD</last_name>
      <phone>252-744-4653</phone>
      <email>kavurum@ecu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Irene Marshall, PA-C</last_name>
      <phone>252-744-5888</phone>
      <email>marshalli@ecu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mani S Kavuru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ecu.edu/pulmonary</url>
    <description>East Carolina University Division of Pulmonary</description>
  </link>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2007</study_first_submitted>
  <study_first_submitted_qc>October 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2007</study_first_posted>
  <last_update_submitted>May 6, 2008</last_update_submitted>
  <last_update_submitted_qc>May 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Mani S. Kavuru, MD, Prinicipal Investigator, Professor and Division Chief Pulmonary &amp; CCM</name_title>
    <organization>East Carolina University</organization>
  </responsible_party>
  <keyword>Pulmonary alveolar proteinosis</keyword>
  <keyword>Primary Pulmonary alveolar proteinosis</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Idiopathic</keyword>
  <keyword>Symptomatic</keyword>
  <keyword>GM-CSF Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

